港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品

智通财经01-14

智通财经APP获悉，再鼎医药(09688)涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日(北京时间上午7点)进行展示。其中，Zocilurtatug pelitecan(Zoci)有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603866383?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603866383","market":"fut","top_or_hot":-1,"title":"港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，再鼎医药(09688)涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日(北京时间上午7点)进行展示。其中，Zocilurtatug pelitecan(Zoci)有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392604.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 11:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1392604.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，再鼎医药(09688)涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日(北京时间上午7点)进行展示。其中，Zocilurtatug pelitecan(Zoci)有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392604.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1392604.html","article_id":"2603866383","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603866383","pubTimestamp":1768360208,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。其中，Zocilurtatug pelitecan有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159760":"医疗健康","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LABU":"三倍做多标普生物-Direxion","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4548":"巴美列捷福持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","XBI":"SPDR S&P Biotech ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","BK1588":"回港中概股","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4581":"高盛持仓","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2054465674.USD":"UBS (LUX) KEY SELEC SICAV DIGITAL TRANSFORMATION T \"P\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","09688":"再鼎医药","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4585":"ETF&股票定投概念","LU1261432733.SGD":"Fidelity World A-ACC-SGD","ZLAB":"再鼎医药","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","XLV":"健康照护类股ETF-SPDR","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC"},"translate_title":"Changes in Hong Kong stocks | Zai Lab (09688) rose more than 7%. The company appeared at the JPM Healthcare Conference. Zoci is expected to become the first globally launched product in the field of oncology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159760":1.5,"LABU":0.6,"ZLAB":1.5,"09688":1.5,"XLV":1.5,"XBI":0.6},"content_text":"智通财经APP获悉，再鼎医药(09688)涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日(北京时间上午7点)进行展示。其中，Zocilurtatug pelitecan(Zoci)有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。目前，再鼎医药在中国拥有八款商业化产品，形成了多元化且可持续的商业化管线组合。呫诺美林曲司氯铵胶囊预计于2026年上半年通过聚焦、高效的商业化策略上市，重点包括医生教育、真实世界的证据生成以及为2027年有望纳入国家医保药品目录做好准备。其他有望近期上市的产品如povetacicept和elegrobart(VRDN-003)将进一步推动区域的业务增长。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603866383","isCrawlerRequest":true}